296 related articles for article (PubMed ID: 29034009)
1. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Scandura JM; Roboz GJ; Moh M; Morawa E; Brenet F; Bose JR; Villegas L; Gergis US; Mayer SA; Ippoliti CM; Curcio TJ; Ritchie EK; Feldman EJ
Blood; 2011 Aug; 118(6):1472-80. PubMed ID: 21613261
[TBL] [Abstract][Full Text] [Related]
3. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
[TBL] [Abstract][Full Text] [Related]
9. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
10. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Gupta N; Miller A; Gandhi S; Ford LA; Vigil CE; Griffiths EA; Thompson JE; Wetzler M; Wang ES
Am J Hematol; 2015 Jul; 90(7):639-46. PubMed ID: 25808347
[TBL] [Abstract][Full Text] [Related]
11. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
14. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
16. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
18. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.
Kavcic M; Fisher BT; Li Y; Seif AE; Torp K; Walker DM; Huang YS; Lee GE; Tasian SK; Vujkovic M; Bagatell R; Aplenc R
Cancer; 2013 May; 119(10):1916-23. PubMed ID: 23436301
[TBL] [Abstract][Full Text] [Related]
19. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
